| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment
|
Wang, Lingling
|
|
|
|
2 |
p. 470-481
|
artikel
|
| 2 |
A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm
|
Li, Peng
|
|
|
|
2 |
p. 405-409
|
artikel
|
| 3 |
Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
|
Joffe, Erel
|
|
|
|
2 |
p. 345-351
|
artikel
|
| 4 |
Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses
|
Fabrizio, Vanessa A.
|
|
|
|
2 |
p. 496-503
|
artikel
|
| 5 |
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis
|
Hamadani, Mehdi
|
|
|
|
2 |
p. 486-494
|
artikel
|
| 6 |
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support
|
Chou, Stella T.
|
|
|
|
2 |
p. 327-355
|
artikel
|
| 7 |
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis
|
Cuker, Adam
|
|
|
|
2 |
p. 664-671
|
artikel
|
| 8 |
An immunocompetent model to uncover the secrets of bispecifics
|
Maakaron, Joseph E.
|
|
|
|
2 |
p. 482-483
|
artikel
|
| 9 |
A novel NUP98-JADE2 fusion in a patient with acute myeloid leukemia resembling acute promyelocytic leukemia
|
Cheng, Chi-Keung
|
|
|
|
2 |
p. 410-415
|
artikel
|
| 10 |
Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice
|
Arthur, Connie M.
|
|
|
|
2 |
p. 527-538
|
artikel
|
| 11 |
Anti–IL-6 cytokine treatment has no impact on elevated hematocrit or splenomegaly in a polycythemia vera mouse model
|
Baldauf, Conny K.
|
|
|
|
2 |
p. 399-404
|
artikel
|
| 12 |
Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis
|
Johnson, Kelly E.
|
|
|
|
2 |
p. 198-211
|
artikel
|
| 13 |
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML
|
Cai, Sheng F.
|
|
|
|
2 |
p. 429-440
|
artikel
|
| 14 |
A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy
|
Badawy, Sherif M.
|
|
|
|
2 |
p. 570-583
|
artikel
|
| 15 |
Baronciani L, Peake I, Schneppenheim R, et al. Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. Blood Adv. 2021;5(15):2987-3001.
|
|
|
|
|
2 |
p. 235
|
artikel
|
| 16 |
Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma
|
Mehta-Shah, Neha
|
|
|
|
2 |
p. 187-197
|
artikel
|
| 17 |
Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma
|
Eertink, Jakoba J.
|
|
|
|
2 |
p. 214-223
|
artikel
|
| 18 |
BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines
|
Diepstraten, Sarah T.
|
|
|
|
2 |
p. 356-366
|
artikel
|
| 19 |
BCR-ABL1 gene rearrangement as a subclonal change in ETV6-RUNX1–positive B-cell acute lymphoblastic leukemia
|
Dun, Karen A.
|
|
|
|
2 |
p. 132-138
|
artikel
|
| 20 |
BiTEs better than CAR T cells
|
Subklewe, Marion
|
|
|
|
2 |
p. 607-612
|
artikel
|
| 21 |
Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses
|
Weycker, Derek
|
|
|
|
2 |
p. 432-439
|
artikel
|
| 22 |
CAR T cells better than BiTEs
|
Molina, John C.
|
|
|
|
2 |
p. 602-606
|
artikel
|
| 23 |
CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia
|
Wintering, Astrid
|
|
|
|
2 |
p. 251-255
|
artikel
|
| 24 |
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort
|
Ghesquières, Hervé
|
|
|
|
2 |
p. 296-308
|
artikel
|
| 25 |
Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S
|
Huynh, Angela
|
|
|
|
2 |
p. 246-250
|
artikel
|
| 26 |
Checkpoints: roadblocks or repairs for the CAR-T journey?
|
Crombie, Jennifer L.
|
|
|
|
2 |
p. 468-469
|
artikel
|
| 27 |
Choosing for whom to recommend allogeneic transplantation for acute myeloid leukemia in CR1: a continued, complicated conversation
|
Menghrajani, Kamal N.
|
|
|
|
2 |
p. 164
|
artikel
|
| 28 |
Chromosomal defects and survival in patients with adult T-cell leukemia/lymphoma after allogeneic HSCT
|
Nakano, Nobuaki
|
|
|
|
2 |
p. 475-486
|
artikel
|
| 29 |
Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib
|
Shenoi, Daniel P.
|
|
|
|
2 |
p. 116-118
|
artikel
|
| 30 |
Clinical and functional significance of circular RNAs in cytogenetically normal AML
|
Papaioannou, Dimitrios
|
|
|
|
2 |
p. 239-251
|
artikel
|
| 31 |
Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
|
Yan, Yuting
|
|
|
|
2 |
p. 441-451
|
artikel
|
| 32 |
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma
|
de Vos, Sven
|
|
|
|
2 |
p. 122-131
|
artikel
|
| 33 |
Commentary on the ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD: reflections based on recent contemporary test data
|
Favaloro, Emmanuel J.
|
|
|
|
2 |
p. 416-419
|
artikel
|
| 34 |
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia
|
Advani, Anjali S.
|
|
|
|
2 |
p. 504-512
|
artikel
|
| 35 |
Cost-effectiveness of diagnostic strategies for venous thromboembolism: a systematic review
|
Zhang, Yuan
|
|
|
|
2 |
p. 544-567
|
artikel
|
| 36 |
Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma
|
Choe, Jee H.
|
|
|
|
2 |
p. 484-496
|
artikel
|
| 37 |
CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies
|
Hu, Yixin
|
|
|
|
2 |
p. 521-527
|
artikel
|
| 38 |
CT-001, a novel fast-clearing factor VIIa, enhanced the hemostatic activity in postpartum samples
|
Sim, Derek S.
|
|
|
|
2 |
p. 287-295
|
artikel
|
| 39 |
Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease
|
Akahoshi, Yu
|
|
|
|
2 |
p. 574-584
|
artikel
|
| 40 |
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
|
Spencer, Andrew
|
|
|
|
2 |
p. 388-398
|
artikel
|
| 41 |
Dasatinib-based 2-step induction for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
|
Sugiura, Isamu
|
|
|
|
2 |
p. 624-636
|
artikel
|
| 42 |
Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm
|
Lai, Hew Yeng
|
|
|
|
2 |
p. 122-131
|
artikel
|
| 43 |
Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details
|
Sanchorawala, Vaishali
|
|
|
|
2 |
p. 216-218
|
artikel
|
| 44 |
Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU
|
Fischer, Kathelijn
|
|
|
|
2 |
p. 369-377
|
artikel
|
| 45 |
DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes
|
Kayamori, Kensuke
|
|
|
|
2 |
p. 438-450
|
artikel
|
| 46 |
Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery
|
Kushnir, Margarita
|
|
|
|
2 |
p. 224-226
|
artikel
|
| 47 |
Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma
|
Barnell, Erica K.
|
|
|
|
2 |
p. 236-245
|
artikel
|
| 48 |
DOACs for VTE in patients with brain cancer and brain metastases: choices, choices, choices
|
Buka, Richard J.
|
|
|
|
2 |
p. 280-282
|
artikel
|
| 49 |
DOACs in patients with brain cancers: promising but still a long way to go
|
Giustozzi, Michela
|
|
|
|
2 |
p. 283-284
|
artikel
|
| 50 |
Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial
|
Gianfaldoni, Giacomo
|
|
|
|
2 |
p. 301-311
|
artikel
|
| 51 |
Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies
|
Baguet, Clémentine
|
|
|
|
2 |
p. 337-342
|
artikel
|
| 52 |
Editorial Board
|
|
|
|
|
2 |
p. i
|
artikel
|
| 53 |
Editorial Board
|
|
|
|
|
2 |
p. i
|
artikel
|
| 54 |
Editorial Board
|
|
|
|
|
2 |
p. i
|
artikel
|
| 55 |
Editorial Board
|
|
|
|
|
2 |
p. i
|
artikel
|
| 56 |
Editorial Board
|
|
|
|
|
2 |
p. i
|
artikel
|
| 57 |
Editorial Board
|
|
|
|
|
2 |
p. i
|
artikel
|
| 58 |
Editorial Board
|
|
|
|
|
2 |
p. i
|
artikel
|
| 59 |
Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia
|
McCalmont, Hannah
|
|
|
|
2 |
p. 296-300
|
artikel
|
| 60 |
Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency
|
Mehic, Dino
|
|
|
|
2 |
p. 391-398
|
artikel
|
| 61 |
Endothelial signaling by neutrophil-released oncostatin M enhances P-selectin–dependent inflammation and thrombosis
|
Setiadi, Hendra
|
|
|
|
2 |
p. 168-183
|
artikel
|
| 62 |
Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy
|
Mukherjee, Sudipto
|
|
|
|
2 |
p. 359-367
|
artikel
|
| 63 |
Evaluation of cyclin A1–specific T cells as a potential treatment for acute myeloid leukemia
|
Leung, Wingchi K.
|
|
|
|
2 |
p. 387-397
|
artikel
|
| 64 |
Expression profiling of snoRNAs in normal hematopoiesis and AML
|
Warner, Wayne A.
|
|
|
|
2 |
p. 151-163
|
artikel
|
| 65 |
Factor XI contributes to myocardial ischemia-reperfusion injury in mice
|
Lorentz, Christina U.
|
|
|
|
2 |
p. 85-88
|
artikel
|
| 66 |
Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas
|
Fleming, Megan
|
|
|
|
2 |
p. 460-472
|
artikel
|
| 67 |
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
|
Botta, Cirino
|
|
|
|
2 |
p. 690-703
|
artikel
|
| 68 |
Front Matter
|
|
|
|
|
2 |
p. ii
|
artikel
|
| 69 |
Gender disparities in allograft access due to HLA-sensitization in multiparous women
|
Fingrut, Warren B.
|
|
|
|
2 |
p. 403-406
|
artikel
|
| 70 |
Genetic ancestry and skeletal toxicities among childhood acute lymphoblastic leukemia patients in the DFCI 05-001 cohort
|
Yao, Song
|
|
|
|
2 |
p. 451-458
|
artikel
|
| 71 |
Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms
|
Alkhateeb, Hassan B.
|
|
|
|
2 |
p. 528-532
|
artikel
|
| 72 |
Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy
|
Yu, Kai
|
|
|
|
2 |
p. 497-511
|
artikel
|
| 73 |
Gioacchino E, Koyunlar C, Zink J, et al. Essential role for Gata2 in modulating lineage output from hematopoietic stem cells in zebrafish. Blood Adv. 2021;5(13):2687-2700.
|
|
|
|
|
2 |
p. 195
|
artikel
|
| 74 |
Heterozygous mutation SLFN14 K208N in mice mediates species-specific differences in platelet and erythroid lineage commitment
|
Stapley, Rachel J.
|
|
|
|
2 |
p. 377-390
|
artikel
|
| 75 |
Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia
|
Çelik, Haydar
|
|
|
|
2 |
p. 367-379
|
artikel
|
| 76 |
High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia
|
Dávila Saldaña, Blachy J.
|
|
|
|
2 |
p. 452-459
|
artikel
|
| 77 |
Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop
|
Fahy, Lucine
|
|
|
|
2 |
p. 513-526
|
artikel
|
| 78 |
Idiopathic purpura fulminans associated with anti-protein S antibodies in children: a multicenter case series and systematic review
|
Theron, Alexandre
|
|
|
|
2 |
p. 495-502
|
artikel
|
| 79 |
Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival
|
Brück, Oscar
|
|
|
|
2 |
p. 274-286
|
artikel
|
| 80 |
Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients
|
Arruda, Lucas C.M.
|
|
|
|
2 |
p. 126-141
|
artikel
|
| 81 |
Impact of graft sources on immune reconstitution and survival outcomes following allogeneic stem cell transplantation
|
Ando, Taiki
|
|
|
|
2 |
p. 408-419
|
artikel
|
| 82 |
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
|
Guglielmelli, Paola
|
|
|
|
2 |
p. 373-375
|
artikel
|
| 83 |
Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors
|
Wakamatsu, Manabu
|
|
|
|
2 |
p. 105-115
|
artikel
|
| 84 |
Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy
|
Dahiya, Saurabh
|
|
|
|
2 |
p. 686-689
|
artikel
|
| 85 |
Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide
|
Rambaldi, Benedetta
|
|
|
|
2 |
p. 352-364
|
artikel
|
| 86 |
Incidence and clinical impact of bleeding events in older patients with acute venous thromboembolism
|
Ferrazzini, Elisa
|
|
|
|
2 |
p. 205-213
|
artikel
|
| 87 |
Increased age-associated B cells in patients with acquired aplastic anemia correlate with IFN-γ
|
Solomou, Elena E.
|
|
|
|
2 |
p. 399-402
|
artikel
|
| 88 |
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma
|
Lemonnier, François
|
|
|
|
2 |
p. 539-548
|
artikel
|
| 89 |
Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways
|
Witte, Hanno M.
|
|
|
|
2 |
p. 637-651
|
artikel
|
| 90 |
Kwun J, Burghuber C, Manook M, et al. Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates. Blood Adv. 2017;1(24):2115-2119.
|
|
|
|
|
2 |
p. 89
|
artikel
|
| 91 |
Laminin G1 residues of protein S mediate its TFPI cofactor function and are competitively regulated by C4BP
|
Teraz-Orosz, Adrienn
|
|
|
|
2 |
p. 704-715
|
artikel
|
| 92 |
Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD
|
Socié, Gérard
|
|
|
|
2 |
p. 184-186
|
artikel
|
| 93 |
Long-term outcomes after autologous stem cell transplantation for multiple myeloma
|
Nishimura, Katherine K.
|
|
|
|
2 |
p. 422-431
|
artikel
|
| 94 |
Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study
|
Bader, Peter
|
|
|
|
2 |
p. 416-428
|
artikel
|
| 95 |
Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis
|
Piran, Siavash
|
|
|
|
2 |
p. 158-167
|
artikel
|
| 96 |
Manipulating hemoglobin oxygenation using silica nanoparticles: a novel prospect for artificial oxygen carriers
|
Devineau, Stéphanie
|
|
|
|
2 |
p. 90-94
|
artikel
|
| 97 |
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma
|
Stroh, Jacob
|
|
|
|
2 |
p. 515-520
|
artikel
|
| 98 |
Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2
|
Nishiwaki, Satoshi
|
|
|
|
2 |
p. 584-592
|
artikel
|
| 99 |
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia
|
Balasundaram, Nithya
|
|
|
|
2 |
p. 652-663
|
artikel
|
| 100 |
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial
|
Jerkeman, Mats
|
|
|
|
2 |
p. 407-415
|
artikel
|
| 101 |
Mulder DT, Mahé ER, Dowar M, et al. CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling. Blood Adv. 2018;2(23):3506-3514.
|
|
|
|
|
2 |
p. 121
|
artikel
|
| 102 |
Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival
|
Chen, Tianzeng
|
|
|
|
2 |
p. 429-440
|
artikel
|
| 103 |
Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine
|
Zátopková, Martina
|
|
|
|
2 |
p. 368-372
|
artikel
|
| 104 |
Myers G, Wang Y, Wang Q, et al. Murine erythroid differentiation kinetics in vivo under normal and anemic stress conditions. Blood Adv. 2023;7(19):5727-5732.
|
|
|
|
|
2 |
p. 336
|
artikel
|
| 105 |
N-acetylcysteine inhibits thrombosis in a murine model of myeloproliferative neoplasm
|
Craver, Brianna M.
|
|
|
|
2 |
p. 312-321
|
artikel
|
| 106 |
Natural history of albuminuria in a large cohort of children and adolescents with sickle cell anemia from Brazil
|
Belisário, André Rolim
|
|
|
|
2 |
p. 365-368
|
artikel
|
| 107 |
NCF1 (p47phox)–deficient chronic granulomatous disease: comprehensive genetic and flow cytometric analysis
|
Kuhns, Douglas B.
|
|
|
|
2 |
p. 136-147
|
artikel
|
| 108 |
Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.
|
|
|
|
|
2 |
p. 252
|
artikel
|
| 109 |
Neutrophil specific granule and NETosis defects in gray platelet syndrome
|
Aarts, Cathelijn E.M.
|
|
|
|
2 |
p. 549-564
|
artikel
|
| 110 |
Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior
|
Wang, Siao-Yi
|
|
|
|
2 |
p. 324-335
|
artikel
|
| 111 |
Origins of bloodstream infections following fecal microbiota transplantation: a strain-level analysis
|
Eshel, Adi
|
|
|
|
2 |
p. 568-573
|
artikel
|
| 112 |
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics
|
Torka, Pallawi
|
|
|
|
2 |
p. 253-262
|
artikel
|
| 113 |
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy
|
Landsburg, Daniel J.
|
|
|
|
2 |
p. 132-135
|
artikel
|
| 114 |
Oxygen gradient ektacytometry–derived biomarkers are associated with acute complications in sickle cell disease
|
Rab, Minke A. E.
|
|
|
|
2 |
p. 276-286
|
artikel
|
| 115 |
Park EJ, Prajuabjinda O, Soe ZY, et al. Exosomal regulation of lymphocyte homing to the gut. Blood Adv. 2019;3(1):1-11.
|
|
|
|
|
2 |
p. 119
|
artikel
|
| 116 |
Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition
|
Kong, Tim
|
|
|
|
2 |
p. 611-623
|
artikel
|
| 117 |
Pharmacological profiling of a berbamine derivative for lymphoma treatment
|
Xu, Senlin
|
|
|
|
2 |
p. 309-323
|
artikel
|
| 118 |
p16INK4A-dependent senescence in the bone marrow niche drives age-related metabolic changes of hematopoietic progenitors
|
Hellmich, Charlotte
|
|
|
|
2 |
p. 256-268
|
artikel
|
| 119 |
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer
|
Hisada, Yohei
|
|
|
|
2 |
p. 487-495
|
artikel
|
| 120 |
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
|
Sehn, Laurie H.
|
|
|
|
2 |
p. 533-543
|
artikel
|
| 121 |
Poor outcome with hematopoietic stem cell transplantation for bone marrow failure and MDS with severe MIRAGE syndrome phenotype
|
Sarthy, Jay
|
|
|
|
2 |
p. 120-125
|
artikel
|
| 122 |
PPARγ increases HUWE1 to attenuate NF-κB/p65 and sickle cell disease with pulmonary hypertension
|
Jang, Andrew J.
|
|
|
|
2 |
p. 399-413
|
artikel
|
| 123 |
Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy
|
Buechner, Jochen
|
|
|
|
2 |
p. 593-601
|
artikel
|
| 124 |
Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States
|
Bewersdorf, Jan Philipp
|
|
|
|
2 |
p. 376-385
|
artikel
|
| 125 |
Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial
|
Iyer, Swaminathan P.
|
|
|
|
2 |
p. 353-364
|
artikel
|
| 126 |
Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies
|
Drazer, Michael W.
|
|
|
|
2 |
p. 146-150
|
artikel
|
| 127 |
Protein S antibody as an adjunct therapy for hemophilia B
|
Wilson, Hope P.
|
|
|
|
2 |
p. 441-452
|
artikel
|
| 128 |
P-selectin–deficient mice to study pathophysiology of sickle cell disease
|
Bennewitz, Margaret F.
|
|
|
|
2 |
p. 266-273
|
artikel
|
| 129 |
Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
|
Zinzani, Pier Luigi
|
|
|
|
2 |
p. 590-599
|
artikel
|
| 130 |
Quantitative proteomics of plasma vesicles identify novel biomarkers for hemoglobin E/β-thalassemic patients
|
Kittivorapart, Janejira
|
|
|
|
2 |
p. 95-104
|
artikel
|
| 131 |
Rapid removal of phagosomal ferroportin in macrophages contributes to nutritional immunity
|
Flannagan, Ronald S.
|
|
|
|
2 |
p. 459-474
|
artikel
|
| 132 |
Recapitulation of posttransfusion purpura by cross-strain platelet immunization in mice
|
Bougie, Daniel W.
|
|
|
|
2 |
p. 287-295
|
artikel
|
| 133 |
Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice
|
Patel, Seema R.
|
|
|
|
2 |
p. 105-115
|
artikel
|
| 134 |
Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease
|
Leonard, Alexis
|
|
|
|
2 |
p. 227-234
|
artikel
|
| 135 |
Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma
|
Kumar, Shaji
|
|
|
|
2 |
p. 367-376
|
artikel
|
| 136 |
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia
|
Hill, Brian T.
|
|
|
|
2 |
p. 378-387
|
artikel
|
| 137 |
Response to “Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study”
|
Neofytos, Dionysios
|
|
|
|
2 |
p. 420-421
|
artikel
|
| 138 |
Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis
|
Menon, Neethu
|
|
|
|
2 |
p. 142-145
|
artikel
|
| 139 |
Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis
|
Masciulli, Arianna
|
|
|
|
2 |
p. 380-386
|
artikel
|
| 140 |
Sex differences in the trajectory of glomerular filtration rate in pediatric and murine sickle cell anemia
|
Kasztan, Malgorzata
|
|
|
|
2 |
p. 263-265
|
artikel
|
| 141 |
Short NJ, Rafei H, Daver N, et al. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv. 2020;4(24):6117-6126.
|
|
|
|
|
2 |
p. 366
|
artikel
|
| 142 |
Significant differences in single-platelet biophysics exist across species but attenuate during clot formation
|
Oshinowo, Oluwamayokun
|
|
|
|
2 |
p. 432-437
|
artikel
|
| 143 |
Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors
|
Thompson, Ella R.
|
|
|
|
2 |
p. 503-508
|
artikel
|
| 144 |
Specifications of the variant curation guidelines for ITGA2B/ITGB3: ClinGen Platelet Disorder Variant Curation Panel
|
Ross, Justyne E.
|
|
|
|
2 |
p. 414-431
|
artikel
|
| 145 |
Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications
|
Pulte, E. Dianne
|
|
|
|
2 |
p. 116-119
|
artikel
|
| 146 |
Targeted deep sequencing in primary myelofibrosis
|
Tefferi, Ayalew
|
|
|
|
2 |
p. 105-111
|
artikel
|
| 147 |
Targeting IGF2BP3 enhances antileukemic effects of menin-MLL inhibition in MLL-AF4 leukemia
|
Lin, Tasha L.
|
|
|
|
2 |
p. 261-275
|
artikel
|
| 148 |
TGF-β1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice
|
Haribhai, Dipica
|
|
|
|
2 |
p. 139-151
|
artikel
|
| 149 |
The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question
|
O'Brien, Sarah H.
|
|
|
|
2 |
p. 679-685
|
artikel
|
| 150 |
The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11
|
Lafage-Pochitaloff, Marina
|
|
|
|
2 |
p. 386-398
|
artikel
|
| 151 |
The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles
|
Webb, Gabriela M.
|
|
|
|
2 |
p. 76-84
|
artikel
|
| 152 |
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study
|
Aldoss, Ibrahim
|
|
|
|
2 |
p. 196-204
|
artikel
|
| 153 |
The impact of in utero transfusions on perinatal outcomes in patients with alpha thalassemia major: the UCSF registry
|
Schwab, Marisa E.
|
|
|
|
2 |
p. 269-279
|
artikel
|
| 154 |
Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database
|
Fallah, Jaleh
|
|
|
|
2 |
p. 112-121
|
artikel
|
| 155 |
Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
|
Hirayama, Alexandre V.
|
|
|
|
2 |
p. 453-467
|
artikel
|
| 156 |
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
|
Fabrizio, Vanessa A.
|
|
|
|
2 |
p. 600-610
|
artikel
|
| 157 |
Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth
|
Lemaitre, Léa
|
|
|
|
2 |
p. 672-678
|
artikel
|
| 158 |
Tounsi WA, Madgett TE, Avent ND. Complete RHD next-generation sequencing: establishment of reference RHD alleles. Blood Adv. 2018;2(20):2713-2723.
|
|
|
|
|
2 |
p. 120
|
artikel
|
| 159 |
Tumor-associated antigen–specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma
|
Dave, Hema
|
|
|
|
2 |
p. 473-485
|
artikel
|
| 160 |
Utility of serum free light chain ratio in response definition in patients with multiple myeloma
|
Abdallah, Nadine
|
|
|
|
2 |
p. 322-326
|
artikel
|
| 161 |
Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL
|
Hamadeh, Lina
|
|
|
|
2 |
p. 148-157
|
artikel
|
| 162 |
Venetoclax–based low intensity therapy in molecular failure of NPM1-mutated AML
|
Jimenez-Chillon, Carlos
|
|
|
|
2 |
p. 343-352
|
artikel
|
| 163 |
Vesicular trafficking is a key determinant of the statin response in acute myeloid leukemia
|
Krosl, Jana
|
|
|
|
2 |
p. 509-514
|
artikel
|
| 164 |
von Willebrand disease: proposing definitions for future research
|
Connell, Nathan T.
|
|
|
|
2 |
p. 565-569
|
artikel
|
| 165 |
von Willebrand factor/ADAMTS13 ratio at presentation of acute ischemic brain injury is predictive of outcome
|
Taylor, Alice
|
|
|
|
2 |
p. 398-407
|
artikel
|
| 166 |
VpreB surrogate light chain expression in B-lineage ALL: a report from the Children's Oncology Group
|
Winter, Stuart S.
|
|
|
|
2 |
p. 585-589
|
artikel
|
| 167 |
When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression
|
Palladini, Giovanni
|
|
|
|
2 |
p. 212-215
|
artikel
|
| 168 |
Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations
|
Sadler, Brooke
|
|
|
|
2 |
p. 420-428
|
artikel
|
| 169 |
Wu Y-J, Hou M, Liu H-X, et al; Cooperative ITP Working Group. A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. Blood Adv. 2020;4(22):5846-5857.
|
|
|
|
|
2 |
p. 365
|
artikel
|
| 170 |
Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination
|
Jamani, Kareem
|
|
|
|
2 |
p. 152-159
|
artikel
|
Tijdschrift beschrijving